NEW YORK (GenomeWeb News) – The European Union plans to fund new research seeking to establish the clinical utility of epigenetic biomarkers for blood-based diseases under its Blueprint consortium program, a €30 million ($39.8 million) effort focused on advancing hematopoietic biomarkers.

The Blueprint program is supporting several projects to speed the development, validation, and use of epigenetic biomarkers in treating diseases such as myeloid and lymphoblastic leukemias, myelodysplastic syndromes, lymphomas, and type 1 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.